Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by pathogenic autoantibodies that bind to membrane proteins at the neuromuscular junction. Most patients have autoantibodies against the acetylcholine receptor (AChR), but a subset of patients have au...
Auteurs principaux: | Takata, K, Stathopoulos, P, Cao, M, Mané-Damas, M, Fichtner, M, Benotti, E, Jacobson, L, Waters, P, Irani, S, Martinez-Martinez, P, Beeson, D, Losen, M, Vincent, A, Nowak, R, O'Connor, K |
---|---|
Format: | Journal article |
Publié: |
American Society for Clinical Investigation
2019
|
Documents similaires
-
Diagnostic use of autoantibodies in myasthenia gravis.
par: Leite, M, et autres
Publié: (2010) -
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
par: Miriam L. Fichtner, et autres
Publié: (2022-10-01) -
Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis
par: Gomez, A, et autres
Publié: (2016) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
par: Miriam L Fichtner, et autres
Publié: (2022-01-01) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
par: Miriam L. Fichtner, et autres
Publié: (2022-01-01)